Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ISM3091 · XL309

Small molecule · Inhibitor of ubiquitin specific protease 1 (USP1) · developed by Exelixis

Phase 1 Most advanced trial
EXEL Developer
1 Registered trials

What is ISM3091?

ISM3091 (XL309) is an orally bioavailable small molecule that binds and inhibits the deubiquitinating enzyme USP1, blocking its deubiquitinating activity. USP1 regulates the Fanconi anemia complex and translesion synthesis in DNA repair. It is being studied in advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
XL309
Drug type
Small molecule
Targets
ubiquitin specific protease 1 (USP1)
Mechanism
Inhibitor of ubiquitin specific protease 1 (USP1)
Pathways
DNA damage repair, Fanconi anemia pathway, translesion synthesis, replication fork protection
Therapy area
Oncology
Developer
Exelixis (EXEL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05932862 Phase 1 Advanced Solid Tumor Active not recruiting EXEL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid Tumor

Other drugs acting on USP1

More from Exelixis

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the EXEL page.

Follow EXEL, the company behind ISM3091

See EXEL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EXEL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.